April 24, 2008 -
MicroIslet, Inc. (OTCBB: MIIS), a biotechnology company engaged in the development and commercialization of cell transplantation therapies for diabetes, and
DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes, announced the award of an NIH grant for "Improving porcine islet function and in vivo survival."
Under the NIH grant, MicroIslet will lead studies utilizing DiaKine's proprietary compounds designed to develop agents capable of enhancing the immunocompatibility and survival of encapsulated porcine islets in vivo...
MicroIslet's Press Release -
[PDF] DiaKine's Press Release -
April 24, 2008 - MicroIslet, Inc. (OTCBB: MIIS), a biotechnology company engaged in the development and commercialization of cell transplantation therapies for diabetes, and DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes, announced the award of an NIH grant for "Improving porcine islet function and in vivo survival."
Under the NIH grant, MicroIslet will lead studies utilizing DiaKine's proprietary compounds designed to develop agents capable of enhancing the immunocompatibility and survival of encapsulated porcine islets in vivo... MicroIslet's Press Release - [PDF] DiaKine's Press Release -
